Cargando…
Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products
BACKGROUND AND OBJECTIVES: In 2010, an intravenous immunoglobulin (IVIG) product was removed from the market due to an association with serious thromboembolic events. Investigations revealed that factor XIa (FXIa) was present as a process‐related impurity. This study investigated the ability of two...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359487/ https://www.ncbi.nlm.nih.gov/pubmed/33277936 http://dx.doi.org/10.1111/vox.13046 |